Greg Harrison
Stock Analyst at B of A Securities
(4.57)
# 269
Out of 5,182 analysts
105
Total ratings
58.75%
Success rate
21.6%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $569 → $626 | $571.73 | +9.49% | 6 | Mar 31, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $26.62 | +91.59% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $436.27 | +27.90% | 8 | Feb 13, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $34 | $32.92 | +3.28% | 9 | Dec 24, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $13.49 | +122.39% | 3 | Oct 27, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $28.96 | +7.04% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $8.79 | +127.53% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $74.59 | -23.58% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $322.11 | +39.70% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.41 | +2,586.20% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $8.36 | +318.66% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $45.04 | +22.11% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $3.49 | +444.41% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $38.55 | -4.02% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $11.21 | +132.04% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $40.79 | -50.97% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.67 | -10.18% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $27.43 | +45.83% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $66.32 | +13.09% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $14.19 | +26.85% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $34.33 | -65.05% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.25 | +497.13% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.94 | +410.20% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $11.49 | -73.89% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.87 | +7,919.25% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $11.94 | +352.26% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $77.50 | +16.13% | 5 | Mar 14, 2022 |
United Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $569 → $626
Current: $571.73
Upside: +9.49%
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $26.62
Upside: +91.59%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $436.27
Upside: +27.90%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $34
Current: $32.92
Upside: +3.28%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $13.49
Upside: +122.39%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $28.96
Upside: +7.04%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $8.79
Upside: +127.53%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $74.59
Upside: -23.58%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $322.11
Upside: +39.70%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.41
Upside: +2,586.20%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $8.36
Upside: +318.66%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $45.04
Upside: +22.11%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.49
Upside: +444.41%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $38.55
Upside: -4.02%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $11.21
Upside: +132.04%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $40.79
Upside: -50.97%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.67
Upside: -10.18%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $27.43
Upside: +45.83%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $66.32
Upside: +13.09%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $14.19
Upside: +26.85%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $34.33
Upside: -65.05%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.25
Upside: +497.13%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.94
Upside: +410.20%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $11.49
Upside: -73.89%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.87
Upside: +7,919.25%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $11.94
Upside: +352.26%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $77.50
Upside: +16.13%